Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Inclusion Criteria: * Newly diagnosed disease of 1 of the following histologic types: * Focal anaplastic Wilms' tumor * Diffuse anaplastic Wilms' tumor * Clear cell sarcoma of the kidney * Malignant rhabdoid tumor (renal or extrarenal) * Renal cell carcinoma * Clear cell * Papillary * Renal medullary * Oncocytoid * Sarcomatoid * Chromophobe * Translocation * Collecting duct * Carcinoma associated with neuroblastoma * Renal cell carcinoma unclassified * Specimens/materials must be submitted for central review by Day 7 * Patients must begin protocol therapy on AREN0321 by Day 14 after surgery or biopsy (surgery/biopsy is Day 0), unless medically contraindicated * Karnofsky performance status (PS) must be \>= 50 for patients \> 16 years if age and Lansky PS must be \>= 50 for patients =\< 16 years of age * Patients must not have received systemic chemotherapy or radiation therapy prior to treatment on this study UNLESS they were enrolled on the AREN0532 or AREN0533 studies and received prenephrectomy chemotherapy for what was originally presumed to be favorable histology Wilms tumor; additionally, patients with pediatric RCC who previously received chemotherapy for another type of malignancy (not the RCC) or non-malignant condition may enroll on the study * Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\] or serum glutamic pyr…